Status:
UNKNOWN
Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients
Lead Sponsor:
Peking University People's Hospital
Conditions:
Leukemia
Myelodysplastic Syndrome
Eligibility:
All Genders
55-70 years
Brief Summary
The purpose of this study is to determine whether the new RIC regimen, containing of low dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged and/or intolerable...
Eligibility Criteria
Inclusion
- diagnosed of hematologic malignant disease
- will undergo HLA matced HSCT
- age \>=55years
- \<55year and intolerable to standard myeloablative conditioning
Exclusion
- KPS status \<70
- cardiac EF\<50%
- creatine clearance \<50 ml/min
- ALT more than 10 times of upper normal limit
Key Trial Info
Start Date :
February 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01828619
Start Date
February 1 2013
Last Update
April 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China, 100044